Analysed VERRICA PHARMACEUTICALS INC (VRCA:NASDAQ) News Sources
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting
09-04-2026
yahoo.com
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
06-04-2026
yahoo.com
Verrica Pharmaceuticals Inc (VRCA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...
11-03-2026
yahoo.com
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
11-03-2026
yahoo.com
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
05-03-2026
yahoo.com
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
23-02-2026
yahoo.com
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
09-02-2026
yahoo.com
What is the current price of VERRICA PHARMACEUTICALS INC (VRCA:NASDAQ)?
The current price of VERRICA PHARMACEUTICALS INC (VRCA:NASDAQ) is $5.56.
VERRICA PHARMACEUTICALS INC (VRCA:NASDAQ) absolute price change since previous trading day?
The absolute price change of VERRICA PHARMACEUTICALS INC (VRCA:NASDAQ) since the previous trading day is $0.45.
VERRICA PHARMACEUTICALS INC (VRCA:NASDAQ) percentage price change since previous trading day?
The percentage price change of VERRICA PHARMACEUTICALS INC (VRCA:NASDAQ) since the previous trading day is 8.8063%.
What is the most recent average sentiment score for VERRICA PHARMACEUTICALS INC (VRCA:NASDAQ)?
The most recent average sentiment score for VERRICA PHARMACEUTICALS INC (VRCA:NASDAQ) is 89 out of 100.
What is the most recent average sentiment for VERRICA PHARMACEUTICALS INC (VRCA:NASDAQ)?
The most recent sentiment for VERRICA PHARMACEUTICALS INC (VRCA:NASDAQ) is .
SEC-8K** Filing Available For VERRICA PHARMACEUTICALS INC (VRCA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.